Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
The objective of this trial is to study the efficacy of treatment of human papilloma virus
(HPV) related oropharyngeal cancer with chemotherapy followed by Transoral Robotic Surgery
(TORS) as definitive treatment. Current treatment of oropharyngeal cancer are
chemo-radiotherapy. There is significant lifelong side effects associated with this approach
related to tissue effects of radiotherapy. The side effects results in significant quality of
life deterioration among the patients. Overall there is 20% failure rate with this treatment
approach. The study hypothesis is that treatment with upfront (neoadjuvant) chemotherapy
followed by transoral surgery and neck dissection is highly effective treatment allowing
competitive cure rate compared to chemo-radiotherapy with less than 10% failure rate, while
avoiding radiotherapy in majority of cases. It is also hypothesized that better functional
and quality of life outcome maybe achieved with this approach.
Phase:
Phase 2
Details
Lead Sponsor:
Nader Sadeghi
Collaborator:
McGill University Health Centre/Research Institute of the McGill University Health Centre